Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Xilio Therapeutics is a biotech company developing tumor-activated immuno-oncology therapies that localize immune responses within the tumor microenvironment to enhance efficacy and reduce systemic toxicity. Its pipeline includes antibody, cytokine, and T cell engager candidates, leveraging proprietary masking platforms. The company focuses on innovative, highly selective treatments for solid tumors, with collaborations and a strong intellectual property portfolio supporting its mission to improve cancer outcomes.
This description was generated via AI from an annual report. Updated about 1 year ago.